February 27, 2024
2 min watch
Save
VIDEO: Vevye demonstrates bioavailability, tolerability in dry eye treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
TAMPA, Fla. — In this Healio Video Perspective from Telling It Like It Is, Priya M. Mathews, MD, MPH, explains why she offers Vevye for the treatment of dry eye disease.
According to Mathews, Vevye (cyclosporine ophthalmic solution 0.1%, Harrow) addresses two important factors of dry eye treatment: bioavailability and patient tolerability.
“I’ve been very impressed with the results, which are in line with what the studies have shown as well,” she said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Mathews reports consulting for Allergan, Harrow and Sun Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.